Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $29.5 million versus the consensus estimate of $29.5 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.